| Date | Title | Description |
| 19.08.2026 | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям | Российская фармкомпания стала лидером по выплатам врачам и медорганизациям Иностранные игроки все меньше тратят на исследования
«Р-Фарм» потратил на выплаты врачам и организациям в 2025 году 2,2 млрд руб., больше, чем любой другой член Ассо... |
| 15.07.2026 | Минздрав впервые зарегистрировал препарат по итогам инспекции за рубежом | Минздрав впервые зарегистрировал препарат по итогам инспекции за рубежом Eisai получила регудостоверение, хотя не проводила клинисследований в России
Японская фармкомпания Eisai 1 июля получила регудостоверение на свой новый препарат против... |
| 10.07.2026 | «Круг добра» будет обеспечивать терапией детей с врожденным ихтиозом | «Круг добра» будет обеспечивать терапией детей с врожденным ихтиозом
Экспертный совет фонда «Круг добра» одобрил включение врожденного ихтиоза в перечень заболеваний, лечение которых оплачивает фонд. После утверждения решения попечительским... |
| 08.07.2026 | Defense Tech Soars: Quantum Systems Lands $1.2 Billion Amid Industry Boom | Quantum Systems clinched $1.2 billion in Series D funding, achieving an $8 billion valuation. Blackstone, Noteus, Airbus, and Advent co-led the round. The German company specializes in AI-powered autonomous drones and advanced defense syste... |
| 03.07.2026 | Quantum Systems raises $1.2B, IQM becomes first European quantum company on major US exchange, and European startup funding in June | This week, we tracked more than 55 tech funding deals worth over €1.6 billion and over 10 exits, M&A transactions, rumours, and related news stories across Europe.
If email is more your thing, you can always subscribe to our newsletter ... |
| 01.07.2026 | Ipsen to acquire Memo Therapeutics for up to EUR 700 million |
French biopahram company Ipsen and Schlieren-based Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeu... |
| 29.06.2026 | Andera Partners joins the European Life Sciences Coalition (ELSC) with the aim to support the mobilization of capital for life sciences innovation in Europe. | Andera Partners joins the European Life Sciences Coalition (ELSC), alongside Forbion, HealthCap, Novo Holdings, Omega Funds, Sofinnova Partners, Van Lanschot Kempen, VIB, BioInnovation Institute, 4BIO Capital, Cooley and Covington.
Launched... |
| 24.04.2026 | Kurma Partners: €215 Million Biofund IV Closes As Total AUM Reach €1 Billion | Kurma Partners, a Paris-based European healthcare venture capital firm and Eurazeo group company, has announced the final closing of Biofund IV at €215 million, bringing total assets under management across all Kurma Partners franchises to ... |
| 03.11.2025 | The Billion-Dollar Biology of Oncology: What Really Drives Pharma’s Appetite? | By Jonathan Tobin, Partner – Brandon Capital
Plenty is written about the trends in dollars and modalities being invested in oncology by VCs. But equally important are the exits, and for early-stage investors M&A is especially important.... |
| 24.10.2025 | Enpal secures €700M ABS facility, Lakestar calls time on generalist venture funds, and 15% of Slush alumni become founders | This week, we tracked more than 70 tech funding deals worth over €1.3 billion, and over 10 exits, M&A transactions, rumours, and related news stories across Europe.
In addition to this week's top financials, we've also indexed the most ... |
| 22.10.2025 | Ipsen to acquire ImCheck Therapeutics, in Andera Partners’ portfolio, expanding its leadership in oncology, strengthening its pipeline | Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImCheck Therapeutics, a private French ... |
| 22.10.2025 | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion | EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
Wed, Oct 22, 2025 09:20 CET Report this content
Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agre... |
| 22.10.2025 | Ipsen expands oncology portfolio with €1B acquisition of French biotech ImCheck Therapeutics | Pharmaceutical company Ipsen has acquired ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies.
ImCheck was founded in 2015 based on the research of Professor Daniel Olive, Direct... |
| 15.10.2025 | Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4 | Lead program from TriSTAR T cell engager platform targets Nectin-4, a clinically validated tumor antigen overexpressed across multiple solid tumors, including urothelial cancer, NSCLC, TNBC, and esophageal cancer
Collaboration with the Nati... |
| 26.03.2025 | Photocure appoints Jane Healy as Vice President and General Manager EMEA | Photocure appoints Jane Healy as Vice President and General Manager EMEA
Wed, Mar 26, 2025 08:00 CET Report this content
Press Release – Oslo, Norway, March 26, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the... |
| 19.03.2025 | Ipsen announces issuance of €500 million inaugural Rated Public Bond | Transaction follows Investment Grade ratings assignment from both S&P and Moody’s
PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today announced the successful comple... |
| 14.11.2024 | Navigating the Future of Biopharma: Sobi's Meeting and TRexBio's Funding Surge | In the ever-evolving landscape of biopharmaceuticals, two significant events recently captured the industry's attention. Swedish Orphan Biovitrum AB (Sobi) announced an Extraordinary General Meeting, while TRexBio secured a hefty $84 millio... |
| 11.11.2024 | Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) | Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
Mon, Nov 11, 2024 08:00 CET Report this content
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Ex... |
| 05.11.2024 | Sobi's New Leadership: A Strategic Shift in the Biopharmaceutical Landscape | In the ever-evolving world of biopharmaceuticals, leadership changes can signal new directions and strategies. Recently, Swedish Orphan Biovitrum AB (Sobi) announced the nomination of David Meek as the new Chair of the Board of Directors. T... |
| 05.11.2024 | Navigating Change in Biopharma: Leadership Shifts at Senhwa and Sobi | The biopharmaceutical landscape is a dynamic arena, where leadership changes can signal new directions and strategies. Recently, two companies, Senhwa Biosciences and Swedish Orphan Biovitrum AB (Sobi), have made significant appointments th... |
| 04.11.2024 | David Meek is proposed as new Chair of the Board of Directors of Sobi | David Meek is proposed as new Chair of the Board of Directors of Sobi
Mon, Nov 04, 2024 21:00 CET Report this content
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of... |
| 16.10.2024 | ‘It feels like we are being punished for creating jobs’ - Coffee shop owner | A coffee shop owner and chef has said he fears he will lose business from tourism if he is forced to raise his prices, writes Jada Bas.
Four years ago, Martin Hernandez, 39, bought the Aroma Coffee Shop, outside Donegal town, which has been... |
| 03.09.2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share
Tweet
Share
Share
Email
Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 13.08.2024 | Myrobalan Therapeutics: Additional $9 Million Raised And Grant Bogle Joins Board | Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unmet need central nervous system (CNS) conditions, announced the appointment of Grant C. Bog... |
| 26.07.2024 | Sanyou Bio Congratulates Eluminex Biosciences and Foreseen Biotechnology on Major Breakthroughs in Innovative Drug Project | SHANGHAI, July 26, 2024 /PRNewswire/ -- On July 15, Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient in the United States. This clinical... |
| 08.05.2024 | TalkTRx™ launched to Improve Pharma Field Rep Conversations with HCPs | ACTO today announced the availability of TalkTRx™, the first product built to provide reps access to marketing assets with overlaid context so they can present accurately and in a more personal way to health care providers (HCPs). TalkTRx f... |
| 07.05.2024 | ACTO LAUNCHES TALKTRX™ TO IMPROVE PHARMA FIELD REP CONVERSATIONS WITH HCPs | Unveiled Today at the 2024 Veeva Commercial Summit, One of the Largest Gatherings of
Commercial and Medical Professionals in Life Sciences
BOSTON, May 7, 2024 /PRNewswire/ - ACTO today announced the availability of TalkTRx™, the first produ... |
| 22.04.2024 | Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases | Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration
Following development candidate validation, Ipsen will assume responsibility for further development and commercializ... |
| 07.03.2024 | Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital | - |
| 13.11.2023 | Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC) | Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition
ZUG, Switzerland and PARIS, Nov. 13, 2023 /PRNewswire/ -- Today, Ipsen (Euronext: IPN) (ADR: IPSEY... |
| 09.01.2023 | Ipsen to Buy Albireo | Ipsen (Euronext: IPN: ADR: IPSEY), a Boulogne Billancourt, France-based biopharmaceutical company focused on advancing medicines in oncology, rare disease and neuroscience, acquired Albireo (Nasdaq: ALBO), a Boston, MA-based provider of bil... |
| 09.01.2023 | Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases | Ipsen and Albireo announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases. The anticipat... |
| 25.01.2022 | Our pledge: summaries in plain language for all journal publ... | BY Will Gattrell
Today, we are broadening our commitment to providing everyone with the opportunity to read and understand our research. From July 2022, we will publish, as a minimum, a 250-word plain language summary alongside all company-... |
| 17.12.2021 | Ipsen : Genfit Collaboration – 17 December 2021 | Disclaimer: Intended for international media and investor audiences only
Ipsen and GENFIT enter into exclusive licensing agreement for
elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as
part of a long-term global pa... |
| 27.10.2021 | Our pledge: industry-leading action for the climate | Today, we proudly stand together with more than 1000 companies worldwide who have pledged to tackle climate change and reduce greenhouse-gas (GHG) emissions as part of the Business Ambition for 1.5°C campaign, spearheaded by the United Nati... |
| 12.10.2021 | Reuters Events Pharma 2021: Transforming Medical Affairs to ... | By Steven Hildemann, MD, PhD, EVP, Chiel Medical Officer
Today at Reuters Events Pharma 2021, I was honoured to speak with Izzy Gladstone about best-in-class medical affairs and how the patient- and physician-centric transformation of the m... |
| 02.08.2021 | Ipsen continues its shopping spree with a $1B-plus deal for Exicure's next-gen oligonucleotides | Ipsen has been on a deal-making spree the last few weeks, shelling out more than a billion dollars in two separate deals to work on a mid-stage levodopa-induced dyskinesia (LID) candidate and a preclinical BAX inhibitor in s... |
| 29.07.2021 | Ipsen : delivers strong H1 2021 results and upgrades full-year... | We are pleased to announce our strong H1 2021 financial results with Group sales of €1 350.3MM and overall growth of 11% (versus H1-2020). We are updating our 2021 guidance to more than 8% in sales growth and around 32% core operating margi... |
| 28.07.2021 | US sells Wu-Tang Clan album to cover Shkreli debt; OrbiMed backs GSK vets' Chinese startup | Martin Shkreli became a top target for ridicule and anger in the mid-2010s when he and his biotech Turing Pharmaceuticals raised the price of a life-saving medicine from $13.50 to $750 per pill. But he also gained notoriety ... |
| 27.07.2021 | Ipsen : BAKX collaboration-27 July 2021 | Disclaimer: Intended for international media and investor audiences only
Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway... |
| 15.07.2021 | Ipsen bets up to $363M on another shot at a debilitating condition related to Parkinson's disease | Ipsen is in a deal-making mood. On Thursday, the company put down $28 million upfront and another $335 million in biobucks for the rights to IRLAB’s mid-stage candidate for levodopa-induced dyskinesia (LID) — a condition ... |
| 18.06.2021 | Ipsen : A year-long partnership with the ISPC | A year-long partnership with the ISPC
This year, Ipsen is partnering with the Institut de Santé Parasport Connecté (ISPC) to sponsor Gaëlle Edon, a high-level athlete. She is also vice-president of ISPC Synergies and a member of the French ... |
| 17.06.2021 | IPSEN S.A.
Ipsen : launches Perspectives Matter around World Kidney Cance... | We need to talk about how we're feeling is the theme of World Kidney Cancer Day (WKCD) on 17 June 2021. To support this theme, Ipsen is launching Perspectives Matter; a social media campaign that brings to life the experiences and perspecti... |
| 17.06.2021 | IPSEN
Ipsen : launches Perspectives Matter around World Kidney Cance... | We need to talk about how we're feeling is the theme of World Kidney Cancer Day (WKCD) on 17 June 2021. To support this theme, Ipsen is launching Perspectives Matter; a social media campaign that brings to life the experiences and perspecti... |
| 05.06.2021 | IPSEN
Ipsen : World Environment Day 2021 | 5 June is World Environment Day, an annual opportunity for self-reflection, education and action around our planet's greatest environmental challenges. This year's theme is ECOSYSTEM RESTORATION.
At the launch of our group strategy, Focus. ... |
| 28.05.2021 | IPSEN
Ipsen : Our 2020 Integrated Annual Report now available for download | As a new CEO, you conducted a strategic review - what were your key learnings?
We have identified solid foundations we can build on: we have a robust specialty care portfolio with leading market shares. Somatuline® is a treatment of choice ... |
| 27.04.2021 | IPSEN
Ipsen : What working in rare disease has taught me about supporting better FOP clinical practice | By Dr Rolf Morhart
My journey to help make an impact
I first became interested in pediatrics during a 3-year stay abroad in a South African hospital in the late 1970s. It was there that I realized how much I value the open nature of young p... |
| 13.11.2020 | Does Perfect Customer Service Make Sense? | investigation and research dna, virus, bacteriagetty |
| 03.09.2010 | Santhera and Ipsen enter into licensing agreement for Fipamezole for the treatment of Dyskinesia in Parkinson's Disease | Santhera Pharmaceuticals (SIX: SANN) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced a license agreement for the development and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside o... |
| - | Unlocking asset potential: addressing unmet needs in oncology through external innovation | Reality of tough-to-treat cancers
For many difficult-to-treat cancers, like metastatic pancreatic cancer and hepatocellular carcinoma, survival outcomes for patients remain poor. In fact, beyond standard of care in both first- and second-li... |
| - | Combatting Rare Pediatric Disease: Ipsen to Sell Priority Review Voucher | Ipsen has agreed to sell its rare pediatric disease priority review voucher to a large global pharmaceutical company in exchange for a cash payment of $158 million at the closing of the transaction.
Orrick represented Ipsen.
The FDA’s rare ... |
| - | Orrick Advises Ipsen on Acquisition of Kartos Therapeutics for up to $1.75 Billion | Ipsen (Euronext: IPN; ADR: IPSEY) has agreed to acquire Kartos Therapeutics for up to $1.75 billion. Under the terms of the agreement and plan of merger, Ipsen, through a fully-owned subsidiary, will pay $450 million upfront at closing. Kar... |
| - | Evolving the treatment sequence for metastatic pancreatic cancer | Pancreatic cancer is poised to surpass colorectal cancer as the 2nd leading cause of cancer-related deaths in the United States by 2020.[1]With multiple high-profile diagnoses over the past few years vaulting the disease into the public con... |
| - | Ipsen’s $247M Epizyme acquisition brings approved cancer drug & more in pipeline | Ipsen has been reshaping its drug lineup by striking deals and its latest one is a $247 million agreement to acquire Epizyme, a cancer drug developer with one commercialized product and a pipeline of additional therapeutic candidates.
The k... |
